Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine
The Trump administration has killed two awards worth $766 million to help Moderna develop a bird flu vaccine, according to the company.
Related Articles
Merck nears $10bn deal for respiratory drugmaker Verona
US pharma giant seeks to expand footprint beyond cancer treatment as its biggest product nears patent cliff
Roche’s venture arm chief to step down in 2026; AstraZeneca obesity leader has retired
→ Carole Nuechterlein said on LinkedIn that she is retiring as head of the Roche Venture Fund “next spring.” Nuechterlein has held this position since…
FDA’s top cell and gene therapy leaders exit agency in ongoing CBER changes
FDA’s Center for Biologics Research and Evaluation fires Nicole Verdun and Rachael Anatol from cell and gene therapy leadership; Director Vinay Prasad adds new roles.
Exclusive: Kennedy picks for vaccine advisory board were paid experts against Merck in civil cases
Two of HHS Secretary Robert F. Kennedy Jr.’s new appointees to the CDC’s vaccine advisory board have previously served as paid expert witnesses for plaintiffs…
Anti-Vaccine Activists Among New US CDC Vaccine Advisors
HHS Secretary Kennedy’s new ACIP appointments include multiple members of anti-vaccine groups and people who have spread misinformation about COVID-19 vaccines.
FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people
FDA approves Moderna’s mNEXSPIKE Covid vaccine for ages 12+ with risk factors and all 65+. CEO Stéphane Bancel welcomes approval of shot that uses lower…
HHS stands firm on new Covid shot guidance for kids. But CDC’s vaccine schedule shows otherwise
The CDC officially axed Covid shot recommendations for pregnant women from its vaccine schedule, following a social media announcement earlier this week from HHS chief…
Summit says bispecific misses overall survival in closely-watched lung cancer study
Summit Therapeutics’ ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug’s regulatory future unclear after mixed EGFR+ NSCLC…
The fate of Moderna’s next-gen Covid shot looms large after a flurry of policy changes
The US’ stance on Covid-19 vaccines under HHS chief Robert F. Kennedy Jr. is coming into focus with a new approval framework, new immunization guidance…
Live today at 3 p.m. ET: Is biotech sentiment really as bad as it seems?
Post-Hoc Live to discuss John Carroll’s Endpoints 100 survey on biopharma industry sentiment, featuring Kyle LaHucik, addressing Trump impact & market concerns